Amgen announced the presentation of efficacy and safety data from the CodeBreaK 100 phase 1/2 trial in patients with KRAS G12C-mutated advanced pancreatic cancer who received Lumakras (sotorasib). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results